Somboonviboon Dujrath, Aramareerak Pattanapol, Lertamornpong Amornchai, Piyavechviratana Kunchit, Pirompanich Pattarin
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Phramongkutklao Hospital, Bangkok, 10400, Thailand.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Thammasat University, Pathumthani 12120, Thailand.
J Infect Dev Ctries. 2024 Dec 31;18(12.1):S318-S325. doi: 10.3855/jidc.19332.
Coronavirus disease 2019 (COVID-19) is associated with long-term symptoms, but the spectrum of these symptoms remains unclear. We aimed to identify the prevalence and factors associated with persistent symptoms in patients at the post-COVID-19 outpatient clinic.
This cross-sectional, observational study included hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients followed-up at a post-COVID-19 clinic between September 2021 and January 2022. Persistent symptoms, defined as lasting > 4 weeks after infection, were analyzed alongside symptom timing (28-90, 91-120, and > 120 days) and associated factors using multivariate analysis.
Among 277 patients, mean (SD) age was 56 (16.6) years, and 58.5% were male. Of these, 80.9% reported at least one persistent symptom. Common symptoms included dyspnea (48.2%), insomnia (42.4%), and myalgia (42.1%). In multivariate analysis, being female [odds ratio (OR) 3.41; 95% confidence interval (CI) 1.5-7.76], and oxygen therapy (OR 3.39; 95% CI 1.3-8.81) were independently associated factors with persistent symptoms. High-sensitivity C-reactive protein (HsCRP) (> 75 mg/dL) was an independent risk factor for dyspnea (adjusted OR 2.29; 95% CI 1.28-4.12), and fatigue (adjusted OR 2.24; 95% CI 1.25-4). Oxygen therapy was an independent risk factor for neurologic symptoms, i.e. insomnia (adjusted OR 2.05; 95% CI 1.15-3.65), and brain fog (adjusted OR 2.02; 95% CI 1.14-3.58).
There was a high prevalence of persistent COVID-19 symptoms. The most common symptom was dyspnea. Female gender and oxygen supplementation were independent associated factors. Continuous follow-up of these patients is still required.
2019冠状病毒病（COVID-19）与长期症状相关，但这些症状的范围仍不清楚。我们旨在确定COVID-19门诊患者中持续症状的患病率及相关因素。
这项横断面观察性研究纳入了2021年9月至2022年1月期间在一家COVID-19门诊接受随访的住院严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者。对持续症状（定义为感染后持续超过4周）进行分析，并结合症状出现时间（28 - 90天、91 - 120天和超过120天）以及使用多变量分析的相关因素。
277例患者中，平均（标准差）年龄为56（16.6）岁，58.5%为男性。其中，80.9%报告至少有一种持续症状。常见症状包括呼吸困难（48.2%）、失眠（42.4%）和肌痛（42.1%）。在多变量分析中，女性[比值比（OR）3.41；95%置信区间（CI）1.5 - 7.76]和氧疗（OR 3.39；95% CI 1.3 - 8.81）是与持续症状独立相关的因素。高敏C反应蛋白（HsCRP）（> 75 mg/dL）是呼吸困难（调整后OR 2.29；95% CI 1.28 - 4.12）和疲劳（调整后OR 2.24；95% CI 1.25 - 4）的独立危险因素。氧疗是神经症状（即失眠，调整后OR 2.05；95% CI 1.15 - 3.65）和脑雾（调整后OR 2.02；95% CI 1.14 - 3.58）的独立危险因素。
COVID-19持续症状的患病率很高。最常见的症状是呼吸困难。女性性别和氧疗是独立相关因素。仍需要对这些患者进行持续随访。
